XRAY vs. NVST, IBRX, GKOS, IONS, HALO, CYTK, MASI, RVMD, OGN, and LNTH
Should you be buying DENTSPLY SIRONA stock or one of its competitors? The main competitors of DENTSPLY SIRONA include Envista (NVST), ImmunityBio (IBRX), Glaukos (GKOS), Ionis Pharmaceuticals (IONS), Halozyme Therapeutics (HALO), Cytokinetics (CYTK), Masimo (MASI), Revolution Medicines (RVMD), Organon & Co. (OGN), and Lantheus (LNTH). These companies are all part of the "medical" sector.
Envista (NYSE:NVST) and DENTSPLY SIRONA (NASDAQ:XRAY) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.
DENTSPLY SIRONA received 428 more outperform votes than Envista when rated by MarketBeat users. Likewise, 61.21% of users gave DENTSPLY SIRONA an outperform vote while only 39.44% of users gave Envista an outperform vote.
Envista has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.
DENTSPLY SIRONA has a net margin of -2.41% compared to DENTSPLY SIRONA's net margin of -4.70%. Envista's return on equity of 11.54% beat DENTSPLY SIRONA's return on equity.
Envista currently has a consensus target price of $25.86, indicating a potential upside of 39.58%. DENTSPLY SIRONA has a consensus target price of $35.22, indicating a potential upside of 24.55%. Given DENTSPLY SIRONA's higher possible upside, research analysts clearly believe Envista is more favorable than DENTSPLY SIRONA.
Envista has higher earnings, but lower revenue than DENTSPLY SIRONA. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.
95.7% of DENTSPLY SIRONA shares are held by institutional investors. 1.3% of Envista shares are held by company insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Envista had 1 more articles in the media than DENTSPLY SIRONA. MarketBeat recorded 7 mentions for Envista and 6 mentions for DENTSPLY SIRONA. DENTSPLY SIRONA's average media sentiment score of 1.36 beat Envista's score of 1.32 indicating that Envista is being referred to more favorably in the media.
Summary
DENTSPLY SIRONA beats Envista on 11 of the 18 factors compared between the two stocks.
Get DENTSPLY SIRONA News Delivered to You Automatically
Sign up to receive the latest news and ratings for XRAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XRAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DENTSPLY SIRONA Competitors List
Related Companies and Tools
